Targeting opioid dysregulation in depression for the development of novel therapeutics
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Since the serendipitous discovery of the first class of modern antidepressants in the 1950’s, all pharmacotherapies approved by the Food and Drug Administration for major depressive disorder (MDD) have shared a common mechanism of action, increased monoaminergic neurotransmission. Despite the widespread availability of antidepressants, as many as 50% of depressed patients are resistant to these conventional therapies. The significant length of time required to produce meaningful symptom relief with these medications, 4–6 weeks, indicates that other mechanisms are likely involved in the pathophysiology of depression and these mechanisms may yield more viable targets for drug development. For decades, no viable candidate target with a different mechanism of action to that of conventional therapies proved successful in clinical studies. Now several exciting avenues for drug development are under intense investigation. One of these emerging targets is modulation of endogenous opioid tone. This review will evaluate preclinical and clinical evidence pertaining to opioid dysregulation in depression focusing on the role of the endogenous ligands endorphin, enkephalin, dynorphin, and nociceptin/orphanin FQ (N/OFQ) and their respective receptors, mu (MOR), delta (DOR), kappa (KOR), and the N/OFQ receptor (NOP) in mediating behaviors relevant to depression and anxiety. Finally, putative opioid based antidepressants that are being tested in clinical trials, ALKS5461, JNJ–67953964 (formerly LY2456302 and CERC–501) and BTRX–246040 (formerly LY–2940094) will be discussed. This review will illustrate the potential therapeutic value of targeting opioid dysregulation in developing novel therapies for major depression disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Endogenous opioid peptides: multiple agonists and receptors
Lord, J. A. H., Waterfield, A. A., Hughes, J., & Kosterlitz, H. W. (1977) · Nature · doi:10.1038/267495a0 · Cited by 2,485
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 2×
“Moreover, aberrant neuronal firing and synaptic plasticity deficits are characteristic features of rodent models of stress and depression (Duman & Aghajanian, 2012; Howe & Kenny, 2018; Lutz & Kieffer, 2013; Ota & Duman, 2013).”
BackgroundThe NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · cited 2×
“As MDD encompasses a heterogeneous cluster of behavioral symptoms, section 2 of this review will critically evaluate the contribution of opioid receptors in modulating behavioral domains as defined by the NIMH research domain criterion (RDoC) (Insel, 2014), which target specific endophenotypes shared across multiple d…”
BackgroundMolecular mechanisms of opioid receptor-dependent signaling and behavior
Al-Hasani, R., & Bruchas, M. R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318238bba6 · Cited by 1,067
Lai, H. M. X., Cleary, M., Sitharthan, T., & Hunt, G. E. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.031 · Cited by 941
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Di Chiara, G., & Imperato, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24578-5 · Cited by 916
Psychotomimesis Mediated by κ Opiate Receptors
Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M. (1986) · Science · doi:10.1126/science.3016896 · Cited by 857
Reward and aversion in a heterogeneous midbrain dopamine system
Lammel, S., Lim, B. K., & Malenka, R. C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.019 · Cited by 804
Drug dependence: stress and dysregulation of brain reward pathways
Kreek, M. J., & Koob, G. F. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00064-7 · Cited by 696
Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses
Filliol, D., Ghozland, S., Chluba, J., Martin, M., Matthes, H. W. D., Simonin, F., Befort, K., Gavériaux-Ruff, C., Dierich, A., LeMeur, M., et al. (2000) · Nature Genetics · doi:10.1038/76061 · Cited by 672
Social functioning in major depressive disorder
Kupferberg, A., Bicks, L., & Hasler, G. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.07.002 · Cited by 663
The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin κ-Opioid System
Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4458-07.2008 · Cited by 601
Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Pliakas, A. M., Carlson, R. R., Neve, R. L., Konradi, C., Nestler, E. J., & Carlezon, W. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07397.2001 · Cited by 509
Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485
Campbell, D. G., Felker, B. L., Liu, C.-F., Yano, E. M., Kirchner, J. E., Chan, D., Rubenstein, L. V., & Chaney, E. F. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-006-0101-4 · Cited by 458
McMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Morphine use after combat injury in Iraq and post-traumatic stress disorder
Holbrook, T. L., Galarneau, M. R., Dye, J. L., Quinn, K., & Dougherty, A. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903326 · Cited by 429
Sharma, S., & Fulton, S. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.48 · Cited by 424
Cao, J.-L., Covington, H. E., Friedman, A. K., Wilkinson, M. B., Walsh, J. J., Cooper, D. C., Nestler, E. J., & Han, M.-H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3177-10.2010 · Cited by 402
Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence
Walker, B. M., & Koob, G. F. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301438 · Cited by 392 · cited 1×
“Just like other KOR antagonists (Deehan, et al., 2012; Doyon, et al., 2006; Walker & Koob, 2008), JNJ–67953964 (3 and 10 mg/kg PO) treatment markedly reduced the number of drinking bouts and volume of ethanol consumed Pharmacol Ther.”
BackgroundCarlezon, W. A., Béguin, C., DiNieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., Rothman, R. B., Ma, Z., Lee, D. Y.-W., & Cohen, B. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092304 · Cited by 390
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346
Dysfunctional reward processing in depression
Admon, R., & Pizzagalli, D. A. (2015) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2014.12.011 · Cited by 343
Yovell, Y., Bar, G., Mashiah, M., Baruch, Y., Briskman, I., Asherov, J., Lotan, A., Rigbi, A., & Panksepp, J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040535 · Cited by 311
Land, B. B., Bruchas, M. R., Schattauer, S., Giardino, W. J., Aita, M., Messinger, D., Hnasko, T. S., Palmiter, R. D., & Chavkin, C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910705106 · Cited by 301
Social Defeat Stress-Induced Behavioral Responses are Mediated by the Endogenous Kappa Opioid System
McLaughlin, J. P., Li, S., Valdez, J., Chavkin, T. A., & Chavkin, C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300872 · Cited by 253
Wood, S. K., Walker, H. E., Valentino, R. J., & Bhatnagar, S. (2010) · Endocrinology · doi:10.1210/en.2009-1026 · Cited by 251
Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232
Wook Koo, J., Labonté, B., Engmann, O., Calipari, E. S., Juarez, B., Lorsch, Z., Walsh, J. J., Friedman, A. K., Yorgason, J. T., Han, M.-H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.009 · Cited by 231
Response of the μ-opioid system to social rejection and acceptance
Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Wang, H., Ni, L., Walker, S. J., Mickey, B. J., Korycinski, S. T., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.96 · Cited by 225
Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., Walwyn, W., Kieffer, B. L., Takeshima, H., Carroll, F. I., Maidment, N. T., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10331.2003 · Cited by 211
Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Walker, S. J., Mickey, B. J., Koeppe, R. A., Langenecker, S. A., & Zubieta, J.-K. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.185 · Cited by 205
Restraint increases dopaminergic burst firing in awake rats
Anstrom, K. K., & Woodward, D. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300730 · Cited by 181
Krishnan, V., Han, M.-H., Mazei-Robison, M., Iñiguez, S. D., Ables, J. L., Vialou, V., Berton, O., Ghose, S., Covington, H. E., Wiley, M. D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.003 · Cited by 176
McIntyre, R. S., Best, M. W., Bowie, C. R., Carmona, N. E., Cha, D. S., Lee, Y., Subramaniapillai, M., Mansur, R. B., Barry, H., Baune, B. T., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11329 · Cited by 172
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169
Bowers, M. E., Choi, D. C., & Ressler, K. J. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.004 · Cited by 155
Possible antidepressive effects of opioids: Action of buprenorphine
Emrich, H. M., Vogt, P., & Herz, A. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb39483.x · Cited by 152
Dynorphin, dysphoria and dependence: the stress of addiction
Chavkin, C., & Koob, G. F. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.258 · Cited by 149
Kautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fabbri, C., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12959 · Cited by 148
Adult attachment style is associated with cerebral μ‐opioid receptor availability in humans
Nummenmaa, L., Manninen, S., Tuominen, L., Hirvonen, J., Kalliokoski, K. K., Nuutila, P., Jääskeläinen, I. P., Hari, R., Dunbar, R. I. M., & Sams, M. (2015) · Human Brain Mapping · doi:10.1002/hbm.22866 · Cited by 133
van Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H. G., & Peeters, F. (2019) · Psychological Medicine · doi:10.1017/s003329171800199x · Cited by 128
Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion
Chefer, V. I., Bäckman, C. M., Gigante, E. D., & Shippenberg, T. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.171 · Cited by 122
Translational assessment of reward and motivational deficits in psychiatric disorders
Der-Avakian, A., Barnes, S. A., Markou, A., & Pizzagalli, D. A. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5004 · Cited by 122
Kappa Opioid Receptors Regulate Stress-Induced Cocaine Seeking and Synaptic Plasticity
Graziane, N. M., Polter, A. M., Briand, L. A., Pierce, R. C., & Kauer, J. A. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.034 · Cited by 121
Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors
Falcon, E., Browne, C. A., Leon, R. M., Fleites, V. C., Sweeney, R., Kirby, L. G., & Lucki, I. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.38 · Cited by 118
Self-citationDepressive symptoms during buprenorphine treatment of opioid abusers
Kosten, T. R., Morgan, C., & Kosten, T. A. (1990) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(90)90035-o · Cited by 110
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats
Nemeth, C. L., Paine, T. A., Rittiner, J. E., Béguin, C., Carroll, F. I., Roth, B. L., Cohen, B. M., & Carlezon, W. A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1834-7 · Cited by 104
Stubbs, B., Vancampfort, D., Veronese, N., Thompson, T., Fornaro, M., Schofield, P., Solmi, M., Mugisha, J., Carvalho, A. F., & Koyanagi, A. (2017) · Psychological Medicine · doi:10.1017/s0033291717001477 · Cited by 102
Amygdala inputs drive feedforward inhibition in the medial prefrontal cortex
Dilgen, J., Tejeda, H. A., & O'Donnell, P. (2013) · Journal of Neurophysiology · doi:10.1152/jn.00531.2012 · Cited by 97
Epigenetic Regulation of the Kappa Opioid Receptor by Child Abuse
Lutz, P.-E., Gross, J. A., Dhir, S. K., Maussion, G., Yang, J., Bramoulle, A., Meaney, M. J., & Turecki, G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.07.012 · Cited by 96
Ota, K. T., & Duman, R. S. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.022 · Cited by 94
Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy
Nyhuis, P. W., Gastpar, M., & Scherbaum, N. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818638a4 · Cited by 90
Stress-Induced Potentiation of Cocaine Reward: A Role for CRFR1 and CREB
Kreibich, A. S., Briand, L., Cleck, J. N., Ecke, L., Rice, K. C., & Blendy, J. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.91 · Cited by 89
Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study
Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., Zaimovic, A., & Lucchini, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.007 · Cited by 88
Increased phasic activity of VTA dopamine neurons in mice 3 weeks after repeated social defeat
Razzoli, M., Andreoli, M., Michielin, F., Quarta, D., & Sokal, D. M. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.050 · Cited by 76
The Role of Amygdalar Mu-Opioid Receptors in Anxiety-Related Responses in Two Rat Models
Wilson, M. A., & Junor, L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301675 · Cited by 76 · cited 1×
“However, in response to predator odor, another model used to induce physiological and behavioral characteristics of PTSD, DAMGO infusions facilitated exploration and reduced defensive burying (Wilson & Junor, 2008).”
MethodRichards, E. M., Mathews, D. C., Luckenbaugh, D. A., Ionescu, D. F., Machado-Vieira, R., Niciu, M. J., Duncan, W. C., Nolan, N. M., Franco-Chaves, J. A., Hudzik, T., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4195-4 · Cited by 76
Hurd, Y. L., Herman, M. M., Hyde, T. M., Bigelow, L. B., Weinberger, D. R., & Kleinman, J. E. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000319 · Cited by 75
The Anti-Suicidal Potential of Buprenorphine: A Case Report
Striebel, J. M., & Kalapatapu, R. K. (2014) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.47.2.g · Cited by 31
Enkephalin downregulation in the nucleus accumbens underlies chronic stress-induced anhedonia
Poulin, J.-F., Laforest, S., & Drolet, G. (2014) · Stress · doi:10.3109/10253890.2013.850669 · Cited by 22
Cited by
Molecular pathways of major depressive disorder converge on the synapse
Fries, G. R., Saldana, V. A., Finnstein, J., & Rein, T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01806-1 · Cited by 504
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Pérez de la Mora, M., Borroto-Escuela, D. O., Crespo-Ramírez, M., Rejón-Orantes, J. D. C., Palacios-Lagunas, D. A., Martínez-Mata, M. K., Sánchez-Luna, D., Tesoro-Cruz, E., & Fuxe, K. (2022) · Cells · doi:10.3390/cells11111826 · Cited by 21
Metadata
- Authors
- Browne, C. A., & Lucki, I.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 201
- Pages
- 51-76
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2942936997
- Cited by
- 95
- References
- 67
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.